Two Ketamine Brain Studies Point to the Same Moment: The Day After the Infusion
Two new ketamine brain studies looked at very different people with very different tools. Both found something worth watching a day after the infusion. Oxford Health reported that ketamine quieted a brain region tied to negative experiences. Futurity covered a Texas A&M analysis of how brain activity reorganizes in older veterans.
Knowing who will respond is worth more to a practice than any single protocol change. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| Oxford study | 70 healthy volunteers, ketamine versus saline, scanned with 7-Tesla fMRI |
| Oxford finding | Ketamine reduced habenula responses to unpleasant stimuli 24 hours after infusion |
| Texas A&M study | 30 veterans with treatment-resistant depression, 18 on ketamine and 12 on midazolam |
| Texas A&M finding | Brain changes measured at 24 hours were linked to symptom improvement at day 7 |
| The shared thread | Both point at the day after treatment, not the infusion itself |
| The limit | Neither study shows how ketamine relieves depression. Both are early and small |
What Oxford Measured
Erdem Pulcu led the Oxford team, with Catherine Harmer as senior author. They randomized 70 healthy adults to ketamine or a saline placebo. Participants then learned to expect mild electrical stimulation to the hand.
Using high-field 7-Tesla imaging, the researchers watched the habenula. It is a small structure that responds to disappointment and punishment, and helps the brain learn from bad outcomes.
Twenty-four hours after infusion, the habenula responded less to the unpleasant stimulus in the ketamine group. Preliminary evidence suggested those experiences might also be remembered as less negative.
Why the Habenula Matters
The habenula has been a suspect for years. Animal research published in Nature linked ketamine’s sustained antidepressant effect to the lateral habenula.
The Oxford work is among the first to show a comparable effect in living human brains. It also connects to how the brain learns from negative outcomes, a theme in our look at reward learning and cognitive flexibility.
The authors are explicit about the gap. Their participants did not have depression. The study cannot establish that habenula changes cause ketamine’s antidepressant effect in patients.
What Texas A&M Measured
The second study is a secondary analysis of an earlier randomized, double-blind trial. It appeared in Translational Psychiatry. The authors are at Texas A&M, Baylor College of Medicine and the University of the Balearic Islands.
Thirty veterans with treatment-resistant depression received one 40-minute infusion. Eighteen got ketamine at 0.1, 0.25 or 0.5 mg/kg, and twelve got midazolam as an active comparator.
Researchers recorded EEG at baseline, one hour, 24 hours and seven days. They looked at how groups of brain regions shared information, rather than how pairs of regions connected.
What It Found Over a Week
The brain changes shifted over time. The strongest effect came at one hour, with a very large effect size. By 24 hours the pattern had moved to a different frequency band, and parts of it returned by day seven.
The clinically interesting result sat at 24 hours. Greater changes in one measure at that point were associated with greater improvement in depressive symptoms at day seven.
That association landed right at the threshold for statistical significance, and the authors describe it as exploratory. It is a lead, not a finding.
The Sample Sizes Are the Story
Eighteen people received ketamine in the Texas A&M analysis, and they were split across three doses. That leaves roughly six people per dose.
Oxford’s 70 participants is a respectable imaging sample. But healthy volunteers are not the patients who walk into a clinic.
Neither design can tell a practice what to change. Both can tell researchers where to look next.
Why a Response Marker Would Matter
The Texas A&M authors note a hard fact about ketamine. Only about 30 to 50 percent of patients with treatment-resistant depression respond robustly.
Imagine a measure taken the day after a first infusion that predicted response. It would change how treatment courses get planned. Patients unlikely to respond could move on sooner.
Nothing like that exists yet. Individual variation has been a recurring theme, including earlier work suggesting brain response depends on the patient.
The Bottom Line
Two independent groups found something happening at 24 hours. That is a reasonable place for future trials to focus, and nothing more than that yet.
Both studies also used a placebo or active control, which puts them above most mechanism work in this field. The same comparator question shaped the recent trial in bipolar depression. Biological markers are appearing elsewhere too, such as ketamine’s effect on morning cortisol.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical advice. The findings described are early research and do not change current treatment practice.
